Search

中文 / English

Address: No. 35, Simiao Road, Daxing Biomedical Industrial Base, Zhongguancun Science Park, Daxing District, Beijing
 Copyright: Beijing Minhai Biological Technology Co., Ltd.   
Beijing ICP 10007676    Powered by  www.300.cn Beijing    Beijing Public Security No. 110115000037 Internet Drug Information Service Qualification Certificate (Beijing) Non-operating 20150173

Contact

Administrative Office: 010-59613600
Supplier consultation: 010-59613585
Recruitment: 010-59613633
Marketing: 010-59613639
Medical support: 010-59613669

Links:

>
>
>
The focus of the FDA's deployment in 2019 is to promote the improvement of the vaccine supervision system

The focus of the FDA's deployment in 2019 is to promote the improvement of the vaccine supervision system

Release time:
2019/02/28
Page view
According to the website of the State Administration for Market Supervision, the National Drug Supervision and Administration Working Conference was held. Jiao Hong, director of the State Drug Administration, said at the meeting that in 2019, it will promote the improvement of the vaccine supervision system and firmly adhere to the safety bottom line. Strictly implement the power of vaccine supervision, strengthen supervision and inspection, increase the inspection and inspection of vaccine batch issuance, and implement the supervision of case listing.
 
 
At the meeting, Jiao Hong deployed six key tasks in 2019: First, perfect the legal system and implement the "four most stringent" requirements. Actively promote the revision and implementation of laws and regulations, and accelerate the construction of standard systems.
 
 
The second is to deepen the reform of the review and approval system and promote the high-quality development of the pharmaceutical industry. Accelerate the launch of new drugs, fully promote the evaluation of the quality and efficacy of generic drugs, deepen the reform of the medical device review and approval system, and improve the management of cosmetics registration and filing.
 
 
The third is to promote and improve the vaccine supervision system, and firmly adhere to the safety bottom line. Strictly implement the power of vaccine supervision, strengthen supervision and inspection, increase the inspection and inspection of vaccine batch issuance, and implement the supervision of case listing.
 
Fourth, adhere to the concept of risk management and strictly prevent and control risks. Strengthen the supervision and sampling inspection of high-risk key products, and severely crack down on violations of laws and regulations.
 
Fifth, promote scientific research on supervision and improve the modernization of supervision.
 
Sixth, vigorously promote smart supervision and continuously innovate supervision methods.
 
Jiao Hong also put forward three requirements at the meeting: First, it is necessary to strengthen the supervision force, implement the supervision responsibility, compact the responsibility of the main body of the enterprise, and strengthen the responsibility of local management.
 
The second is to strengthen capacity building, consolidate the foundation of supervision, improve the quality management system of the supervision department, establish and improve the drug emergency management mechanism, and promote the improvement of supervision business capabilities.
 
The third is to enhance service awareness, improve supervision efficiency, practice service awareness with action, and establish a new image of drug supervision with clean supervision.